BiotechTube

Tamsulosin + Solifenacin

ApprovedCompleted
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Lower Urinary Tract Symptoms

Conditions

Lower Urinary Tract Symptoms, Overactive Bladder, Benign Prostatic Hyperplasia (BPH)

Trial Timeline

Sep 1, 2007 → Apr 1, 2011

NCT ID
NCT02715024

About Tamsulosin + Solifenacin

Tamsulosin + Solifenacin is a approved stage product being developed by Astellas Pharma for Lower Urinary Tract Symptoms. The current trial status is completed. This product is registered under clinical trial identifier NCT02715024. Target conditions include Lower Urinary Tract Symptoms, Overactive Bladder, Benign Prostatic Hyperplasia (BPH).

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (2)

NCT IDPhaseStatus
NCT01457573ApprovedCompleted
NCT02715024ApprovedCompleted

Competing Products

20 competing products in Lower Urinary Tract Symptoms

See all competitors
ProductCompanyStageHype Score
JSP191Jasper TherapeuticsPhase 1
25
solifenacin succinate + tamsulosin hydrochloride + Placebo to solifenacin + Placebo to tamsulosinAstellas PharmaPhase 2
52
SolifenacinAstellas PharmaPre-clinical
23
Vesitirim™ (Solifenacin)Astellas PharmaPre-clinical
23
Mirabegron + PlaceboAstellas PharmaPhase 2
52
tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg) + tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)Astellas PharmaPhase 3
77
tamsulosin hydrochloride + solifenacin succinate + PlaceboAstellas PharmaPhase 2
52
Tamsulosin + SolifenacinAstellas PharmaApproved
85
Tamsulosin OCASAstellas PharmaApproved
85
DuloxetineShionogiPhase 3
77
Duloxetine + PlaceboShionogiPhase 3
77
AZD1656AstraZenecaPhase 1
33
Nirsevimab + PlaceboAstraZenecaPhase 3
77
RSVpreF + PlaceboPfizerPhase 3
76
GabapentinPfizerApproved
84
Erythropoiesis-stimulating agents (ESAs) + Luspatercept + Lenalidomide + Hypomethylating agents (HMAs) + Reb blood cell transfusionBristol Myers SquibbPre-clinical
22
ALX-0171 1.5 mg/kgSanofiPhase 2
51
ALX-0171 3.0 mg/kg + ALX-0171 6.0 mg/kg + ALX-0171 9.0 mg/kgSanofiPhase 2
51
ALX-0171 Dose 1 + ALX-0171 Dose 2 + PlaceboSanofiPhase 2
51
Placebo + Hydrocodone bitartrateUCBPhase 3
74

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85